 and has proven to only delay cognitive decline for a matter of months. The FDA approved Kisunla after an 18-month study showed patients taking the drug had a 22% slower decline than those who received a placebo. Tom Graham, Fox News. On Wall Street, stock futures are mixed up a little for the Dow, down a bit for the Nasdaq. The morning after, the Nasdaq topped 18,000 for the first time with another record high close. I'm Dave Anthony. This is Fox News.